



- Non-Declaration Statement
 - I have no relevant relationships with ineligible companies to disclose within the past 24 months



- Identify the most common types of vaginitis and differentiate between presenting symptoms
- Discuss co-morbid conditions that interfere with successful treatment of vaginitis, both organic and patientcreated
- Given a clinical scenario, construct a treatment plan for a patient presenting with vaginitis



- Normal vaginal ph is 4.0-4.5
- Usual flora is Lactobacillus
- Self managing organ






Image courtesy Megan Werbel, PAS-II, University of Florida



- Normal vaginal discharge is:
 - Clear to milky
 - Has a subtle scent
 - Changes in thickness and amount depending on the menstrual cycle
- Normal vaginal discharge is not:
 - Irritating
 - Pruritic
 - Foul smelling
 - Yellow/Green/Grey/Bloody






Thin, gray discharge Prominent vaginal Bacterial odor Vaginosis Signs and Symptoms Minimal inflammation No pruritus

Douching Co-Morbid Soaps Conditions Diet Exercise Recurrence of this issue is high and prevention is difficult

What can alter the vaginal pH? Intercourse













- Suppressive therapy for those with 3+/12 months
- Metronidazole x 7-10 days followed by twice weekly
- followed by twice weekly dosing x 4-6 months

 Metrogel 2x/week x 16 weeks
- Clindamycin gel as alternative
- Alternatives:
 - Vaginal health probiotics
 - Vaginal microbiome transplants
- Avoidance of Offending Agent
 - Condoms/Abstinence
 - WSW 25-50% concordant infection rate



- Endometritis
- Pelvic Inflammatory Disease
- Post operative infections
- Pre term delivery



- Treat or not to treat (always the question)?
- Some populations should always be treated:
 - Patients undergoing hysterectomy
 - Patients undergoing termination
- Careful consideration for:
 - Uterine instrumentation**
 - Pregnant patients without history of pre-term birth**



- USPSTF: D recommendations for patients without risk for preterm delivery. I recommendation for patients at increased risk for pre-term birth
- Considerations: within pre-term risk groups, there may be subgroups for which BV becomes the perfect agent for induction of pre-term labor
- Treatment in pregnant patients should be oral agents: topical agents associated with increase in LBW



- Agents:
 - Albicans
 - GlabrataTropicalis
- Overgrowth of C. Albicans (normally found in mouth, vagina, and rectum) can become pathologic



- Obesity
- Warm Climates
- Immunosuppression
- Diabetes
- Pregnancy
- Broad Spectrum Antibiotic use
- Orogenital Sex



- Pruritus
- Erythema
- Edema of vulva and labia
- Satellite pustules
- White, curd-like discharge
- Excoriations




- Diagnosis is KoH prep and saline prep
- •May need culture if recurrent
- **■**pH 4-4.5









- Topical anti-fungal agents
 - Miconazole OTC
 - Clotrimazole OTC
 - Terconazole prescription
- Oral anti-fungal agents
 - •Fluconazole 150 1 now, repeat in 3 days



- Complicated if:
 - Frequent
 - Recurrent (4+/year)
 - Severe
- Immunocompromised patient
- Treatment is based on culture, directed to agent, and longer
 - Example: 600 mg boric acid/vagina x 2weeks or Fluconazole 150 q 3 days x 14 days then recurrence prevention 100 mg q week x 6 months
- Must watch liver function tests



- Skin breakdown
- InvasiveCandidiasis
- Gastrointestinal issues
- Fatigue
- Sexual dysfunction




- Common sexually transmitted infection
- More symptomatic in women than men
- Frequently seen with other infections (esp. N. gonorrhoeae)
- Can incubate for 3d-4w from exposure
- Can infect as high as the bladder




- Urinary frequency
- Dysuria
- Dyspareunia
- Erythema
- •Foul, thin, "frothy" discharge
- Intermenstrual bleeding
- ■Vaginal pruritis



- Pap smear
- Saline preparation
- •Urinalysis
- NAAT/DNA










- Drug of choice is oral metronidazole
 - •7 d course taken BID
 - •Alternatively, tinidazole 2g x l dose

Trichomoniasis Treatment

- Sexual partner should be treated
- Couple should use condoms until partner is treated



- Causes:
 - Decreased estrogen creates a thinned vaginal mucosa and flattened rugae
 - Vaginal squamous epithelium thin
 - Parabasal squamous cells rise in number
 - Mucosa becomes easily friable
- This is an inflammatory reaction that can cause a sloughing of cells



- ■Vaginal Dryness
- Vaginal Pruritis
- Irritation
- Thin, white to light yellow discharge without odor
- "Stuck" labia
- Dyspareunia
- Urinary Symptoms



- Physical Exam is a key component
 - Mons pubis/labia lose bulk
 - Prominent urethral meatus
 - Thinning pubic hair
 Introital narrowing
 - Smooth, shiny, dry vaginal mucosa
 - May have thin, sticky discharge present
 Easily friable tissue in absence of other pathology
- pH >4.6 to as high as 7
- Cytology will show greatly increased parabasal or intermediate cells



- Aimed at local relief of symptoms
 - Only one option will treat both vaginal and systemic (3 month systemic vaginal ring-17B Estradiol)
 - Otherwise 3 month estradiol local only
 - 2 Estrogen creams and one tablet
- Can be used even in patients who have contraindications to estrogen therapy (not all, but most)
- DHEA transforms vaginal epithelium to E2 and androgens
- The SERM ospemifene is an oral tablet that will help treat dyspareunia
- Local Laser therapy to vaginal walls to enhance repair mechanisms



- Urinary urgency, dysuria, urethral eversion, prolapse, and recurrent UTIs are associated with urethral and bladder mucosal
- The relationship between urinary incontinence and low estrogen is very controversial.
 - Relationship may be better found in other issues (higher BMI, new onset diabetes, weight gain)
 - The use of local estrogen may improve periurethral vascularity and reduce detrusor contraction and there is not evidence of harm in otherwise noncontraindicated patients.



• 28 yo G2P2 presents to the office complaining of 5 days of vaginal discharge. Menses ended 7 days ago. The pt is using the Nexplanon implant for contraception. The discharge is thin and mildly pruritic toward the end of the day. The pt is concerned about odor. PMH is significant for DM diagnosed after last pregnancy. Pt is diet controlled and last A1C 2 months ago was 7.4.



- External genitalia are without abnormality. Vagina has no lesions.
 There is no noted erythema. Vault has moderate amount of adherent thin grey discharge with odor. Cervix is parous and closed without CMT.
- Wet prep:





- Diagnosis:
- Bacterial Vaginosis
- Treatment:
- Patient is not pregnant
- Prefers to take oral medication
- No preference on dosingDrink EtOH?
- Insuran
 - Metronidazole 500 mg BID x 7 days
 - Secnidazole 2 g x 1 dose
 - Tinidazole 2 g x 2 days



• 45 yo G1P1 complains of persistent vaginal discharge and itching for the past 3 months. Has been seen twice by separate providers and has just started health insurance. Has tried OTC agents without success for the past month and notes that the pills given at both appointments made things better for a few days each time. Pt is not sexually active. LMP 24 days ago. PMI significant for poorly controlled HTN, currently taking Lisinopril 5 mg.



External genitalia erythematous and vulva with moderate edema. Excoriations noted surrounding labia. Significant erythema in intertrigonal folds. Vagina with significant edema and erythema of walls. Moderate clumpy white discharge noted. No lesions seen. Cervix parous, closed, no lesions or CMT.

• Wet mount:





- Diagnosis:
 - Candida
 - Which subtype
- Need to consider ComplicatedV
 Uncomplicated
- This patient is complicated
 - Needs a culture
 - Needs workup for other causes as well
 Labs for glucose intolerance at a minimum
 - LFTS if long term azole
- Consideration of prevention for future



- All discharge should be evaluated under a microscope
- A recurrent yeast infection should spark your interest and warrant a workup or a referral
- Sex does not stop happening at any age
- Untreated BV has long term complications and is an easy treatment



- Algorithms for Managing Vulvovaginal Symptoms
 - Reichman et al, Current Infectious Diseases, 2019;21(10):40. Epub 2019 Oct
- CDC Treatment Guidelines 2021
 - https://cdc.gov/std/treatmentguidelines/vaginaldischarge.htm
- Vaginitis in Non-Pregnant Patients
- ACOG Practice Bulletin 215, January 2020

